1450 related articles for article (PubMed ID: 23010994)
1. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
3. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.
Fujiyoshi K; Yamamoto G; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Oncol Rep; 2017 Feb; 37(2):785-792. PubMed ID: 28000889
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
[TBL] [Abstract][Full Text] [Related]
6. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
9. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
12. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
Bae JM; Cho NY; Kim TY; Kang GH
Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
[TBL] [Abstract][Full Text] [Related]
14. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
15. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.
Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA
Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864
[TBL] [Abstract][Full Text] [Related]
16. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
18. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
[TBL] [Abstract][Full Text] [Related]
19. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
20. Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer.
Kim B; Park SJ; Cheon JH; Kim TI; Kim WH; Hong SP
World J Gastroenterol; 2014 Apr; 20(15):4370-6. PubMed ID: 24764675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
